Online inquiry

IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11266MR)

This product GTTS-WQ11266MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11266MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4539MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ10251MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ9262MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ15308MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ13240MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ10641MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ10850MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ14653MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW